antibiotics

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
Still too little progress on antibiotic resistance, says O’Neill report update
Still too little progress on antibiotic resistance, says O’Neill report update
Pharmaforum
antibiotics
antibiotic resistance
drug development
Flag link:
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Endpoints
Shionogi
antibiotics
FDA
cefiderocol
nosocomial pneumonia
Flag link:
MGB tops up cash pool to wrap up antibiotic phase 2a
MGB tops up cash pool to wrap up antibiotic phase 2a
Fierce Biotech
MGB Biopharma
antibiotics
MGB-BP-3
C. difficile
clinical trials
Flag link:
Nabriva gets first approval in novel antibiotic class
Nabriva gets first approval in novel antibiotic class
BioCentury
Nabriva
antibiotics
Xenleta
lefamulin
community-acquired bacterial pneumonia
Flag link:
Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another
Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another
BioCentury
Nabriva Therapeutics
antibiotics
lefmulin
Flag link:
CMS prescribes payment fix to resuscitate US antibiotic industry
CMS prescribes payment fix to resuscitate US antibiotic industry
Endpoints
CMS
antibiotics
drug development
Flag link:
Why Merck is in infectious disease for the long haul
Why Merck is in infectious disease for the long haul
BioCentury
Merck
R&D
infectious diseases
antibiotics
Flag link:
U.K. launches subscription model to pay for antibiotics
U.K. launches subscription model to pay for antibiotics
BioCentury
UK
antibiotics
subscription model
Flag link:
In starved antibiotic field, Melinta soars as FDA grants speedy drug review
In starved antibiotic field, Melinta soars as FDA grants speedy drug review
Endpoints
Melinta Therapeutics
antibiotics
Baxdela
community-acquired bacterial pneumonia
FDA
priority review
Flag link:
Once picked as a $500M winner, bankrupt Achaogen auctions off its antibiotic for a fraction of that
Once picked as a $500M winner, bankrupt Achaogen auctions off its antibiotic for a fraction of that
Endpoints
Achaogen
antibiotics
Zemdri
Flag link:
New antibiotic treatments focus of reintroduced Senate bill
New antibiotic treatments focus of reintroduced Senate bill
BioCentury
antibiotics
Senate
antibiotic resistance
Flag link:
The FDA is forcing a small antibiotic player back to the clinic for a new trial — 10 years after first rejection
The FDA is forcing a small antibiotic player back to the clinic for a new trial — 10 years after first rejection
Endpoints
Motif Bio
FDA
antibiotics
Iclaprim
Flag link:
Scientists Tracked Evolution Of Antibiotic Resistance In Real Time
Scientists Tracked Evolution Of Antibiotic Resistance In Real Time
Forbes
Evolution
antibiotics
antibiotic resistance
Flag link:
Immune To Drugs: Antimicrobial Resistance Could Kill 10 Million A Year
Immune To Drugs: Antimicrobial Resistance Could Kill 10 Million A Year
Forbes
antibiotics
antibiotic resistance
Flag link:
Biotech hits the brakes on their PhIII pivotal for a lead antibiotic as investigators track a high rate of kidney injuries
Biotech hits the brakes on their PhIII pivotal for a lead antibiotic as investigators track a high rate of kidney injuries
Endpoints
Polyphor
clinical trials
antibiotics
murepavadin
nosocomial pneumonia
Flag link:
Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge
Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge
Stat
antibiotics
antibiotic resistance
R&D
drug development
Flag link:
Nabriva's Antibiotic Contempo Turned Down by FDA Over Manufacturing Issues
Nabriva's Antibiotic Contempo Turned Down by FDA Over Manufacturing Issues
BioSpace
Nabriva Therapeutics
Contempo
antibiotics
FDA
drug manufacturing
Flag link:
A decade of incentives to promote antibiotic development and still no viable route to commercial success
A decade of incentives to promote antibiotic development and still no viable route to commercial success
BioWorld
Achaogen
Zemdri
R&D
drug development
antibiotics
Flag link:
Forge Therapeutics, Basilea Sign Deal to Pursue New Antibiotics
Forge Therapeutics, Basilea Sign Deal to Pursue New Antibiotics
Xconomy
antibiotics
drug development
Forge Therapeutics
Basilea
Flag link:

Pages